Marleena M1, Nur Fatin Syakirah MR1, Siti Nur Farah Adibah R1, Azzah Hana AY1, Saraswathy A2, Anasufiza Habib1
1. Biochemistry Unit, Specialised Diagnostic Centre, Institute for Medical Research, National Institute of Health, Jalan Pahang, 50588, Kuala Lumpur, Malaysia
2. Endocrine Unit, Specialised Diagnostic Centre, Institute for Medical Research, National Institute of Health, Jalan Pahang, 50588, Kuala Lumpur, Malaysia
*Corresponding author: Marleena Mamat @ Mohamad.
ABSTRACT
INTRODUCTION: Argininosuccinic acid (ASA) is a diagnostic biomarker for argininosuccinic aciduria, a rare urea cycle disorder caused by argininosuccinate lyase (ASL) deficiency. Traditionally, quantification of ASA has relied on ion exchange chromatography (IEC), which, although effective, presents limitations, particularly in terms of specificity and lengthy run times. With growing demand for rapid and reliable metabolic screening, there is a need to adopt more advanced analytical platforms.
OBJECTIVE(S): This study aims to develop, validate, and evaluate the diagnostic performance of a liquid chromatography-mass spectrometry (LC-MS/MS) method for the quantification of ASA.
MATERIALS & METHODS: The new method emphasizes enhanced sample preparation, chromatographic resolution, and mass detection parameters to overcome the analytical challenges associated with ASA measurement. Urine samples were processed through extraction, derivatisation and the addition of stable isotope-labelled internal standards. Analysis was run using a Micromass Quattro micro TMS coupled to a Waters 2795 HPLC system. The method was validated using samples from 1,253 healthy controls, four confirmed ASA patients, and two external quality control patients. Method performance was evaluated in terms of accuracy, sensitivity, specificity, precision and linearity. Statistical analysis was performed using IBM SPSS Statistics version 29.0.
RESULTS: The method demonstrated good linearity, precision (CV <12%), accuracy, and recovery (98–105%). Diagnostic performance showed 100% sensitivity, specificity, and positive predictive value, with no false positives observed. A diagnostic cut-off was established at <400 mmol/mol creatinine, corresponding to the 99th percentile of the control population.
CONCLUSION: This LC-MS/MS method exhibits superior analytical performance compared to IEC approaches, significantly reducing analysis time while enhancing specificity and quantitative accuracy through the use of an internal standard. The transition to this advanced platform represents an important advancement in the analytical workflow for metabolic diagnostics, enabling more reliable and efficient detection of ASA in both clinical and research contexts.
KEYWORDS: Argininosuccinic Aciduria, Argininosuccinate Lyase, LC-MS/MS, Method Validation, Diagnostic Accuracy


